U.S. health insurers seek largest jump in Obamacare premiums since 2018, study shows

U.S. insurers are proposing a median 15% premium increase for Obamacare plans in 2026, the largest jump since 2018, according to a KFF analysis of 105 insurers across 19 states. This significant hike is primarily driven by the impending 2026 expiration of COVID-era premium tax credits, which alone accounts for an additional 4% increase, alongside persistent rising medical costs (up 8% annually, notably due to GLP-1 drugs and labor pressures), slower market growth, and a higher proportion of high-risk enrollees. The proposed increases reflect broader struggles within the industry, with major insurers like UnitedHealth and Centene adjusting profit forecasts, signaling increased cost pressures for consumers and potential shifts in the Affordable Care Act market.

Analysis

U.S. health insurers are signaling significant margin pressure in the Affordable Care Act (ACA) market, proposing a median premium increase of 15% for 2026—the largest since 2018. This rate hike is a direct response to a confluence of negative factors, rather than a reflection of robust profitability. A key driver is policy risk, with the planned 2026 expiration of enhanced premium tax credits compelling insurers to preemptively add 4% to their rate requests. Concurrently, underlying medical cost trends remain elevated at an 8% annual increase, fueled by high-cost GLP-1 drugs and labor pressures impacting provider negotiations. The situation is exacerbated by a deteriorating risk pool, characterized by slower market growth and an influx of higher-risk patients. The tangible impact of these headwinds is already evident, with major insurers like UnitedHealth (UNH) and Centene (CNC) suspending or lowering their annual earnings forecasts, indicating that current premiums are insufficient to cover rising costs and maintain profit targets.

Key Decisions for Investors

• Investors should exercise caution with health insurers heavily exposed to the ACA marketplace, as the combination of an 8% medical cost trend, adverse selection, and policy uncertainty is directly compressing margins, as evidenced by negative guidance from UnitedHealth and Centene.
• Monitor legislative developments regarding the potential extension of premium tax credits beyond 2025; a failure to renew them presents a significant headwind to enrollment and revenue growth for insurers in 2026.
• Scrutinize individual insurers' upcoming medical loss ratios (MLRs) and forward guidance for signs of superior cost management, as the ability to control expenses related to GLP-1 drugs and provider contracts will be a key differentiator for profitability in this challenging environment.